Welcome to our dedicated page for Maze Therapeutics news (Ticker: MAZE), a resource for investors and traders seeking the latest updates and insights on Maze Therapeutics stock.
Maze Therapeutics, Inc. (Nasdaq: MAZE) is a clinical-stage biopharmaceutical company that regularly reports news on the progress of its genetics-guided kidney and metabolic disease programs. Company updates often highlight developments in its lead oral small molecule candidates, MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, as well as broader corporate and financial milestones.
News items from Maze commonly cover clinical trial milestones, such as Phase 1 and Phase 2 study results, enrollment updates, and plans for upcoming proof-of-concept trials. For example, the company has issued press releases on first-in-human data for MZE782 in healthy volunteers, describing safety, pharmacokinetics, and pharmacodynamic markers like urinary amino acid excretion and changes in estimated glomerular filtration rate. It has also provided regular updates on the Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease.
Investors and followers of MAZE can also expect financial results announcements, including quarterly earnings press releases furnished on Form 8-K, which summarize research and development spending, cash position, and license revenue. In addition, Maze issues news about financing transactions, such as its oversubscribed private placement of common stock and pre-funded warrants, along with related registration statements for resale of those securities.
Maze’s news flow also includes corporate governance and leadership updates, such as the appointment of a new chief financial officer and the selection of a new chairman of the board, as well as participation in healthcare and investor conferences where management presents the company’s strategy and pipeline. Conference-related releases typically provide webcast details for investors.
This news page aggregates these disclosures so readers can follow Maze’s clinical progress, financing activities, and corporate developments in one place. For investors and observers tracking MAZE, the feed offers a structured view into how the company’s genetics-based approach and lead programs are evolving over time.
Maze Therapeutics (Nasdaq: MAZE) announced the appointments of Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors, strengthening its clinical, academic and biopharmaceutical leadership.
The company highlighted upcoming milestones for its kidney and metabolic disease pipeline, including additional Phase 2 data for APOL1 inhibitor MZE829 in broad APOL1-mediated kidney disease patients expected in late 2026 or early 2027, and initial Phase 2 data for MZE782, a SLC6A19 inhibitor in development for phenylketonuria and chronic kidney disease, anticipated in 2027. Maze also plans further trial initiations for both molecules in 2027. Dr. Johnson brings more than 30 years of cardiology-focused clinical and research experience and currently serves as President of Wellesley College and a Johnson & Johnson board member. Dr. Kornowski adds over 35 years of industry leadership, including leading Boston Pharmaceuticals and senior partnering and M&A roles at Roche.
Maze Therapeutics (Nasdaq: MAZE) reported second quarter 2026 results and pipeline progress, emphasizing multiple Phase 2 programs and a strengthened balance sheet. Cash, cash equivalents and marketable securities totaled $494.9 million at June 30, 2026, up from $360.0 million at year-end 2025, supported by an April 2026 equity and pre-funded warrant offering that raised approximately $150 million in gross proceeds. Maze expects its current cash to fund operations into 2029.
The Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease continues enrolling three 10–15 patient cohorts, with updated data expected in late 2026 or early 2027 and a pivotal trial targeted for the first half of 2027, subject to regulatory feedback. The Phase 2 CIPheR trial of MZE782 in phenylketonuria has been initiated, with topline data expected in 2027, and a Phase 2 proof-of-concept trial of MZE782 in chronic kidney disease is planned for the first half of 2027. Second quarter 2026 R&D expenses were $34.9 million and G&A expenses were $13.1 million, leading to a net loss of $44.7 million, or $0.76 per share.
Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D., will present at two June 2026 investor conferences focused on healthcare.
He will speak at the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. Live webcasts and 60-day replays will be available on the company’s investor website.
Maze Therapeutics (Nasdaq: MAZE) reported Q1 2026 results and clinical progress. Positive Phase 2 HORIZON data for MZE829 in broad AMKD showed a 35.6% mean proteinuria reduction at week 12, supporting advancement to a pivotal trial planned for 1H 2027, subject to regulatory feedback.
Maze plans two Phase 2 trials of MZE782 in PKU and CKD starting in 2026. Q1 2026 included $20 million in license revenue, net loss of $24.2 million ($0.45/share), and R&D and G&A expenses of $34.1 million and $12.4 million, respectively. Pro forma cash is about $528 million, with runway expected into 2029.
Maze Therapeutics (Nasdaq: MAZE) priced an underwritten registered offering of 5,540,000 common shares at $23.50 per share and offered pre-funded warrants for up to 850,000 shares at $23.499 each. Gross proceeds are expected to be $150 million, before fees.
The offering is expected to close on or about April 23, 2026. Maze intends to use net proceeds to advance R&D for MZE829 (APOL1-mediated kidney disease) and MZE782 (PKU and CKD) and for general corporate purposes. Maze expects cash to fund operations into 2029. Leerink Partners is sole underwriter; several institutional investors are participating.
Maze Therapeutics (Nasdaq: MAZE) reported positive topline Phase 2 HORIZON data for oral APOL1 inhibitor MZE829 on March 25, 2026. At week 12, MZE829 produced a 35.6% mean uACR reduction in broad APOL1-mediated kidney disease (AMKD) patients; 50% achieved >30% uACR reduction.
Subgroups showed a 61.8% mean uACR reduction in FSGS patients and a 48.6% mean uACR reduction in non-diabetic AMKD. Fifteen patients were safety-evaluable and 12 were efficacy-evaluable. No serious adverse events were reported. Maze plans to continue enrollment and advance MZE829 to a pivotal program.
Maze Therapeutics (Nasdaq: MAZE) reported Q4 and full-year 2025 results and clinical progress on March 25, 2026. MZE829 Phase 2 HORIZON topline showed a mean uACR reduction of 35.6% at week 12 in broad AMKD, with 61.8% mean reduction in severe FSGS. Maze plans to advance MZE829 to a pivotal program.
Maze expects to start two Phase 2 MZE782 trials in PKU and CKD in 2026, secured a 20 million milestone for MZE001, added Neil Kumar to its board, and reported $360.0 million cash runway into 2028.
Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 10:30 a.m. ET.
A live webcast will be available in the Investors section of the Maze Therapeutics website and will be archived for 60 days after the presentation.
Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D., will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Feb. 11, 2026 at 3:00 p.m. ET. A live webcast will be available in the Investors section of the Maze Therapeutics website and archived for 60 days.
Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.
A live webcast will be available in the Investors section of Maze Therapeutics' website at www.mazetx.com, and the presentation will be archived for 30 days following the event.